Zosuquidar 3HCl | LY335979 | CAS#167465-36-3 | P-glycoprotein inhibitor | P-gp

MedKoo Cat#: 203220 | Name: Zosuquidar trihydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zosuquidar, also known as LY-335979, is a potent P-glycoprotein (P-gp) inhibitor, which binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents.

Chemical Structure

Zosuquidar trihydrochloride

CAS#167465-36-3 ( HCl)

Theoretical Analysis

MedKoo Cat#: 203220

Name: Zosuquidar trihydrochloride

CAS#: 167465-36-3 ( HCl)

Chemical Formula: C32H34Cl3F2N3O2

Exact Mass: 0.0000

Molecular Weight: 637.00

Elemental Analysis: C, 60.34; H, 5.38; Cl, 16.70; F, 5.97; N, 6.60; O, 5.02

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,350.00	Ready to ship
500mg	USD 2,650.00	Ready to ship
1g	USD 4,250.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

167465-36-3 ( HCl) 167354-41-8 (free base)

Synonym

LY 335979; LY-335979; LY335979; D06387; RS33295198; Zosuquidar HCl; Zosuquidar 3HCl; Zosuquidar trihydrochloride

IUPAC/Chemical Name

(2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol, trihydrochloride

InChi Key

ZPFVQKPWGDRLHL-WITOOOCMSA-N

InChi Code

InChI=1S/C32H31F2N3O2.3ClH/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27;;;/h1-14,21,29-31,38H,15-20H2;3*1H/t21-,29-,30+,31-;;;/m1.../s1

SMILES Code

O[C@@H](COC1=C2C=CC=NC2=CC=C1)CN3CCN([C@@H]4C5=CC=CC=C5[C@]6([H])[C@](C6(F)F)([H])C7=CC=CC=C74)CC3.[H]Cl.[H]Cl.[H]Cl

Appearance

Yellow solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>10 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Related CAS# 167465-36-3( HCl), 167354-41-8 (free base).

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#YXM80727

View CoA: current batch, Lot#YXM90530

QC Data

View QC data: current batch, Lot#YXM90530

View QC data: current batch, Lot#YXM80727

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Zosuquidar (RS 33295-198) trihydrochloride is an inhibitor of P-glycoprotein with a Ki value of 59 nM.

In vitro activity:

Zosuquidar completely or partially restored drug sensitivity in all P-gp-expressing leukemia cell lines tested and enhanced the cytotoxicity of anthracyclines (daunorubicin, idarubicin, mitoxantrone) and gemtuzumab ozogamicin (Mylotarg) in primary AML blasts with active P-gp. In addition, P-gp inhibition by zosuquidar was found to be more potent than cyclosporine A in cells with highly active P-gp. Reference: BMC Cancer. 2008 Feb 13;8:51. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18271955/

In vivo activity:

In vivo microdialysis was used to collect FLZ containing brain and blood dialysates following intravenous (i.v.) drug administration either with or without pretreatment with the specific P-gp inhibitor, zosuquidar trihydrochloride (zosuquidar·3HCl). A sensitive, rapid, and reliable ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) technique was developed and validated to quantitate free FLZ levels in the dialysates. No significant differences were observed in the brain/blood FLZ area under the concentration-time curve (AUC) ratio between normal and PD model rats. However, pretreatment with zosuquidar·3HCl markedly increased the AUC ratio in both rat models. In addition, FLZ penetration was similar in zosuquidar·3HCl-pretreated normal and PD rats. These results suggest that P-gp inhibition increases BBB permeability to FLZ, thereby supporting the hypothesis that P-gp normally restricts FLZ transfer to the brain. Reference: Biomed Res Int. 2014;2014:850493. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25045708/

	Solvent	mg/mL	mM
Solubility
	DMSO	1.0	1.57
	Water	5.0	7.85

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 637.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer. 2008 Feb 13;8:51. doi: 10.1186/1471-2407-8-51. PMID: 18271955; PMCID: PMC2258302.

In vivo protocol:

1. Hou J, Liu Q, Li Y, Sun H, Zhang J. An in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats. Biomed Res Int. 2014;2014:850493. doi: 10.1155/2014/850493. Epub 2014 Jun 23. PMID: 25045708; PMCID: PMC4090575. 2. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol. 2004 Feb;53(2):173-8. doi: 10.1007/s00280-003-0720-y. Epub 2003 Nov 7. PMID: 14605863

1: Infed N, Smits SH, Dittrich T, Braun M, Driessen AJ, Hanekop N, Schmitt L. Analysis of the inhibition potential of zosuquidar derivatives on selected bacterial and fungal ABC transporters. Mol Membr Biol. 2013 Mar;30(2):217-27. doi: 10.3109/09687688.2012.758876. PubMed PMID: 23356389. 2: Abu Ajaj K, Graeser R, Kratz F. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. Breast Cancer Res Treat. 2012 Jul;134(1):117-29. doi: 10.1007/s10549-011-1937-9. Epub 2012 Jan 8. PubMed PMID: 22228402. 3: Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, Tallman MS. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010 Nov 18;116(20):4077-85. doi: 10.1182/blood-2010-04-277269. Epub 2010 Aug 17. PubMed PMID: 20716770; PubMed Central PMCID: PMC2993615. 4: Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID, Raats J, Burgess LJ. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol. 2009 Sep;64(4):763-8. doi: 10.1007/s00280-009-0925-9. Epub 2009 Feb 25. PubMed PMID: 19241078. 5: Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res. 2009 Aug;33(8):1055-61. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23. PubMed PMID: 19108889. 6: Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res. 2009 Jun;33(6):769-74. doi: 10.1016/j.leukres.2008.09.020. Epub 2008 Oct 30. PubMed PMID: 18976810. 7: Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer. 2008 Feb 13;8:51. doi: 10.1186/1471-2407-8-51. PubMed PMID: 18271955; PubMed Central PMCID: PMC2258302. 8: Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2007 Apr;48(4):708-15. PubMed PMID: 17454628. 9: Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res. 2007 Sep;24(9):1720-8. Epub 2007 Mar 23. PubMed PMID: 17380257. 10: Anderson BD, May MJ, Jordan S, Song L, Roberts MJ, Leggas M. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metab Dispos. 2006 Apr;34(4):653-9. Epub 2006 Jan 24. PubMed PMID: 16434546.

1. Rasmus Blaaholm Nielsen, René Holm, Ils Pijpers, Jan Snoeys, Ulla Gro Nielsen, Carsten Uhd Nielsen, Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and in vitro-in vivo correlation of P-glycoprotein inhibition, International Journal of Pharmaceutics: X, Volume 3, 2021, 100089, ISSN 2590-1567, https://doi.org/10.1016/j.ijpx.2021.100089. (https://www.sciencedirect.com/science/article/pii/S2590156721000189)